Year: 2023

InvestEU in Belgium: EIB venture debt for bone therapy innovator Novadip

InvestEU in Belgium: EIB venture debt for bone therapy innovator Novadip

The European Investment Bank (EIB) and Novadip have signed a €18 million venture debt financing agreement supported by the European Union’s InvestEU initiative. The Belgian biotech company will use the funds to support clinical trials of NVD-003, an autologous bone product that provides one-time curative treatment to achieve long-term union

Read More
Repeated Signal Solutions, Inc. and Avari Wireless Inc. announce Enhanced ERCES Monitoring

Repeated Signal Solutions, Inc. and Avari Wireless Inc. announce Enhanced ERCES Monitoring

Repeated Signal Solutions, Inc. (RSS) and Avari Wireless Inc. have announced the launch of Enhanced ERCES Monitoring™.  Enhanced ERCES Monitoring™ is a new service that allows building owners to monitor their First Responder (ERCES) radio systems remotely with the same level of visibility as required by the NFPA code. "Enhanced

Read More
Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs

Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs

Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that the first US patient has been implanted with its investigational tissue regeneration product, NVD-003, in

Read More
Avari Wireless awarded contract to provide radio communications coverage for the Toronto underground subway system pilot project

Avari Wireless awarded contract to provide radio communications coverage for the Toronto underground subway system pilot project

Avari Wireless has announced they are the winner of the tender to supply Distributed Antenna System (DAS) for the Toronto Transit Commission (TTC). The project’s scope is to supply engineering, equipment, materials, and other services to construct a Distributed Antenna System (DAS) using digital technologies, to provide radio communications coverage

Read More
NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting

NorthSea Therapeutics to present ICONA Phase 2b data as an oral late-breaker session at the 2023 AASLD Liver Meeting

NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced that the results of the ICONA phase 2b study for the treatment of NASH, will be presented as an oral late-breaker at the AASLD Liver

Read More
Zeotap Data offers digital media buyers precision and reach against their core demographic audiences. Validated with persistent, factual data, accuracy far exceeds big tech DSPs

Zeotap Data offers digital media buyers precision and reach against their core demographic audiences. Validated with persistent, factual data, accuracy far exceeds big tech DSPs

Zeotap Data, a leading provider of fully-consented, people-based data solutions, is proud to introduce Validated Demos the key to delivering reach and frequency metrics against your core demographic audience in programmatic media buying. Through exclusive partnerships with Europe’s major mobile telco operators, Zeotap Data employs cutting-edge modelling techniques to leverage

Read More
Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update

Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provided a

Read More
NorthSea Therapeutics receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the treatment of Intestinal Failure-Associated Liver Disease

NorthSea Therapeutics receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the treatment of Intestinal Failure-Associated Liver Disease

NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced that one of its novel Structural Engineered Fatty Acids (SEFAs), SEFA-6179, has been granted Rare Pediatric Disease (RPD) Designation by the United States Food and

Read More
Achronix announces FPGA-Powered accelerated Automatic Speech Recognition solution

Achronix announces FPGA-Powered accelerated Automatic Speech Recognition solution

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, is proud to announce its latest innovation in partnership with Myrtle.ai — an accelerated automatic speech recognition (ASR) solution based on the Speedster7t FPGA. This transformative solution converts spoken language to text in over 1,000 concurrent real-time

Read More
Ventyx Biosciences announces positive results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis

Ventyx Biosciences announces positive results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced positive results from the Phase 2 trial of VTX002, a novel oral S1P1 receptor modulator, in patients with moderate-to-severely

Read More
Glydways announces $56 Million Series B Round with New Science Ventures, ACS Group, Khosla Ventures and Gates Frontier

Glydways announces $56 Million Series B Round with New Science Ventures, ACS Group, Khosla Ventures and Gates Frontier

Glydways, a leader in developing on-demand Personal Rapid Transit (PRT), has announced its $56 million Series B round, including the conversion of notes valued at more than $28 million and led by New Science Ventures with participation from The ACS Group and Gates Frontier. Khosla Ventures, Glydways first investor, is

Read More
Paragraf named Business of the Year in Cambridge glory parade

Paragraf named Business of the Year in Cambridge glory parade

Paragraf, the first company in the world to mass produce graphene-based electronic devices using standard semiconductors processes, was named Business of the Year in the 33rd annual Business Weekly Awards on 14 September 2023. Co-founders Simon Thomas – the CEO – and CSO Professor Sir Colin Humphreys received the coveted

Read More